Creative Medical Technology strikes warrant inducement deal, pays CEO bonus

Creative Medical Technology Holdings, Inc. reported in an 8-K dated June 30, 2026 that it had entered into warrant exercise inducement offer letters with holders of warrants originally issued on October 29, 2025. The holders agreed to exercise warrants covering an aggregate of 2,790,340 shares at $1.60 per share, in exchange for the company reducing the exercise price from $2.86 per share and issuing new inducement warrants for 5,580,680 shares, also at $1.60 per share.¹

The gross proceeds from the exercise of the existing warrants totaled approximately $4.5 million before financial advisory fees, and the net proceeds will go toward working capital and general corporate purposes.¹

The shares underlying the existing warrants are registered under a Form S-3 registration statement, file number 333-291713, declared effective by the SEC on December 12, 2025.¹ The new inducement warrants were issued in a private placement under Section 4(a)(2) of the Securities Act.¹ These inducement warrants cannot be exercised until the company obtains stockholder approval under Nasdaq rules, after which they will remain exercisable for five years.¹ The company also agreed to file a resale registration statement on Form S-3 within thirty days of closing to cover the shares underlying the inducement warrants.¹

Roth Capital Partners, LLC served as financial advisor on the transaction and will receive a fee equal to 8% of gross proceeds from the exercise, plus reimbursement of $50,000 in legal expenses.¹

Separately, on July 1, 2026, the company's Compensation Committee approved a $100,000 bonus payment to Chief Executive Officer Timothy Warbington.¹